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1. Introduction 
The rapid growth of the prevalence of Type II Diabetes Mellitus (DM) and its complications 
among adults has become a major public health problem that is approaching epidemic 
proportions worldwide.  The world prevalence of diabetes among adults is estimated to be 
285 million in 2010, and this number is projected to reach 439 million by 2030 (Shaw et al., 
2010).  While the pathogenesis of hyperglycemia in Type I DM is secondary to lack of insulin 
due to islet destruction, the hyperglycemia in Type II DM results from complex genetic 
interactions, the expression of which is modified by environmental factors such as increased 
age, reduced physical activity and obesity (Inzucchi & Sherwin, 2007).  The over-production 
of insulin and the influence of hyperinsulinemia in enhancing free or bioavailable 
concentrations of insulin-like growth factor-1 (IGF-1) have been postulated to increase 
carcinogenesis through a tyrosine kinase growth factor cascade in enhancing tumor cell 
proliferation (Campbell et al., 2010; Giovannucci, 1995; McKeown-Eyssen, 1994; Moore, 
1998). 
Type II DM has been demonstrated by numerous epidemiologic studies to be associated 
with increased risk of many gastrointestinal cancers: esophageal adenocarcinoma, colorectal 
cancer, pancreatic cancer, biliary tract cancers (primary gallbladder carcinoma, 
extrahepatic/intrahepatic cholangiocarcinoma) and hepatocellular carcinoma.  This review 
focuses on the expanding body of clinical evidence that supports the association between 
Type II DM and the increased risk of gastrointestinal cancers.  Implications of Type II DM 
on each respective gastrointestinal cancer are divided into proposed etiology and 
pathophysiology, and review of epidemiologic studies to support the suggestion that Type 
II DM independently increase the risk of gastrointestinal cancers.   
2. Implication of Type II DM on esophageal adenocarcinoma 
2.1 Etiology and pathophysiology 
One of the postulated mechanisms to explain the association between Type II DM and 
esophageal adenocarcinoma is that the metabolic changes associated with DM and 
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adiposity, such as hyperinsulinemia, establishes a hormonal environment which promotes 
the development of nascent tumors (Calle & Kaaks, 2004; Neale et al., 2009).   
Insulin is the hormone integral to the ‘metabolic hormonal hypothesis,’ proposed by Calle 
and colleagues.  Insulin activates the insulin receptor, and consequently the intracellular 
signaling cascades with mitogenic and anti-apoptotic effects.  Insulin also promotes 
synthesis and activity of insulin-like growth factor-1 (IGF-1), a peptide hormone with 
similar structure of insulin, which regulates cellular proliferation in response to available 
energy and reserves (Calle & Kaaks, 2004).  In vitro studies have clearly established that both 
insulin and IGF-1 act as growth factors that promote cell proliferation and inhibit apoptosis 
(Ish-Shalom et al., 1997; Khandwala, 2000; Lawlor & Alessi, 2001; Le Roith, 2000; Prisco et 
al., 1999).   
As hyperinsulinemia is positively associated with the risk of esophageal adenocarcinoma, 
association with type II DM, “a proxy for pre-existing hyperinsulinemia,” was observed 
independently of other obesity-related factors by Neale and colleagues (Neale et al., 2009).  
2.2 Epidemiologic studies 
In a large population-based case-control study in Australia, Neale and colleagues 
observed consistently higher risks of esophageal adenocarcinoma among those with 
diabetes within each category of Body Mass Index (Neale et al., 2009).  People with 
diabetes who were also obese were at a 3.5 fold higher risk of esophageal adenocarcinoma 
than those with neither risk factor (Odds Ratio (OR) 3.55, 95% Confidence Interval (CI) 
1.87-6.76).  Esophageal adenocarcinoma risks were somewhat lower in those with either 
obesity or diabetes alone (Obesity: OR 2.67, 95% CI 1.8-3.96; Diabetes: OR 1.86, 95% CI 
0.65-5.31).  
Hemminki and colleagues also conducted a large population-based study of 125,126 in 
Sweden, which assessed cancer risks in patients who were hospitalized for Type II DM. For 
the entire follow-up period (All: 1 year or 5 years), the risk for esophageal cancer was 
significant in Type II diabetic patients.  Standardized incidence ratio (SIR) for esophageal 
cancer was 2.19 (95% CI 1.83-2.59).  The association between number of hospitalizations and 
esophageal cancer was also observed (Hemminki et al., 2010).  
The case-control study by Neale and colleagues is consistent in demonstrating that Type II 
diabetic patients have about two-fold increased risk of esophageal adenocarcinoma. 
Hemminki et al. also supported the finding that Type II DM is associated with about two-
fold increased risk of esophageal cancer overall; however, no distinction was made between 
adenocarcinoma and squamous cell carcinoma.  
3. Implication of Type II DM on colorectal cancer 
3.1 Etiology and pathophysiology 
Obesity, reduced physical activity and abdominal distribution of adiposity, which are 
determinants of the metabolic syndrome, have been implicated in increased risk of 
colorectal cancer (Giovannucci, 2007; Glade, 1999).  Hyperglycemia and hyperinsulinemia, 
which are the underlying metabolic defects of the metabolic syndrome and are especially 
pronounced during the early state of Type II DM, have been proposed as mediators for 
association between metabolic syndrome and colorectal cancer (Campbell et al., 2010; 
Giovannucci, 1995; McKeown-Eyssen, 1994). 
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Chronic hyperinsulinemia of Type II DM leads to insulin resistance as a metabolic 
adaptation to increased circulating levels of free fatty acids released from adipocytes.  
Increased free fatty acids leads to reduced capacity of livers, muscle and other tissues to 
absorb, store and metabolize glucose (Bergman & Ader, 2000).  In addition to free fatty 
acids, adipocytes also release endocrine signaling factors, adiponectin and leptin, which 
play a role in regulation of insulin sensitivity in liver, muscle and other tissues (Havel, 2002).   
Furthermore, insulin positive feedback influences levels of leptin, a mitogenic 
adipocytokine, which has been demonstrated to be associated with cancers of the colon, 
breast and prostate (Stattin et al., 2003; Tessitore et al., 2000).  
3.2 Epidemiologic studies 
A 2005 meta-analysis of epidemiologic studies reported that DM was associated with a 
moderate increased risk of CRC overall, with almost identical associations when men and 
women were analyzed separately (Larsson et al., 2005).  Analysis of 15 studies (six case-
control and nine cohort studies), with 2,593,935 participants, showed that diabetes was 
associated with an increased risk of colorectal cancer when compared to non-diabetic 
controls (Pooled RR of colorectal cancer incidence = 1.3, 95% CI 1.20-1.40), without 
heterogeneity between studies.  In a Singapore Chinese Health Study of diabetic cohort, 
with distinct body type and lifestyle profiles from those of Western population, Type II 
DM was also statistically significantly associated with colorectal cancer risk in both men 
(RR = 1.5, 95% CI = 1.2-2.1) and women (RR = 1.4, 95% CI = 1.0-1.9) (Seow et al., 2006) 
[Table 1].   
More recent studies, however, consistently demonstrate stronger associations for men than 
for women (Inoue et al., 2006; Kuriki et al., 2007; Limburg et al., 2006; Seow et al, 2006;) 
[Table 1]. Many studies which examine the association between Type II DM and CRC 
published since the 2005 meta-analysis by Larsson, analyze statistics in men and women 
separately in the same study, which suggest that the association among women is not as 
significant relative to men.   
A more recent large, prospective cohort-study by Campbell et al. demonstrated the 
association between Type II DM and CRC among men (RR 1.24, 95% CI 1.08-1.44), but not 
among women (RR 1.01, 95% CI 0.82-1.23) (Campbell et al., 2010).  Limburg and colleagues 
have also supported a statistically significant relationship between Type II DM and CRC 
(especially proximal colon CRC vs. distal CRC) in men, but not statistically significant in 
women.  Over 19,158 person-years of follow-up, 51 incident CRC cases were identified 
within the type 2 DM cohort of 1,975, while only 36.8 cases were expected based on data 
from the general population (Standardized Incidence Ratio (SIR) = 1.39, 95% CI 1.03-1.82).  
In men, Type II DM was associated with increased overall (SIR = 1.67, 95% CI 1.16-2.33) and 
proximal (SIR = 1.96, 95% CI 1.16-3.10) CRC risks, with statistically not significant increase 
in distal CRC risk.  Conversely, in women, Type II DM was not a risk factor for overall, 
proximal or distal CRC (SIR = 1.03, 95% CI 0.60-1.66; SIR = 1.17, 95% CI 0.58-2.09; and SIR = 
0.74, 95% CI 0.24-1.72, respectively) (Limburg et al., 2006) [Table 1].  
Large population-based case-control studies conducted by Ren et al. in China, and by Kuriki 
et al. and Inoue et al. in Japan, established that association between Type II DM and CRC is 
statistically significant in both men and women; however, Type II DM women showed less 
pronounced risk for CRC compared to Type II men (Inoue et al., 2006; Kuriki et al., 2007: 
Ren et al., 2009).  Kuriki and colleagues studied the associations between Type II DM and 
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multi-site cancer risks in a case-control study of 11,672 cancer cases (5341 men, 6331 women) 
and 47,768 cancer-free controls.  Adjusted for confounding factors such as age, BMI, alcohol, 
smoking, physical exercise, bowel movement, family history of CRC, family history of DM, 
vegetable intake and dietary restriction, past/present history of diabetes was associated 
with increased CRC risk for both men and women (OR=1.3, 95% CI 1.0-1.65, OR=1.13, 95% 
CI 0.72-1.76, respectively) (Kuriki et al., 2007).  A more significant association between Type 
II DM and CRC was observed by Ren and colleagues in their population-based case-control 
study conducted in China (SIR = 1.82, 95% CI 1.23-2.4 in Type II DM men, SIR = 1.36, 95% CI 
0.85-1.88 in Type II DM women) (Ren et al., 2009).  Inoue and colleagues have observed 
moderately increased risk of colon CA in diabetic men (HR 1.36, 95% CI 1.0-1.85) and rectal 
CA in diabetic women (HR 1.65, 95% CI 0.8-3.39), without statistically significant increase of 
colon CA in diabetic women and rectal CA in diabetic men.   
 
Study Control Case 
Adjusted Risk for 
Colorectal Cancer 
Adjustment 
Seow et al. 
Non-Diabetic          
(Cases of CRC)         
55,851 (546) 
Diabetic              
(Cases of CRC)        
5,469 (90) 
RR = 1.5                
(95% CI 1.2-1.8) 
Age, Sex, Dialect group, Education, Body 
Mass Index, Smoking, Alcohol, Familial Hx 
of CRC, Physical activity 
Inoue et al. 
Non-Diabetic †         
(Cases of Colon CA)    
43,451 (445) 
Diabetic †             
(Cases of Colon CA)    
3,097 (46) 
HR = 1.36              
(95% CI 1.0-1.85 )  
 
Non-Diabetic ‡         
(Cases of Colon CA)    
49,652 (293) 
Diabetic ‡             
(Cases of Colon CA)    
1,571 (10) 
HR = 0.83              
(95% CI 0.42-1.61) 
Age, Study area, Hx of cerebrovascular 
disease, Hx of ischemic heart disease, 
Smoking, Alcohol, Body Mass Index, 
Physical activity, Vegetable intake, Coffee 
intake 
 
Non-Diabetic †         
(Cases of Rectal CA)    
43,451 (228) 
Diabetic †             
(Cases of Rectal CA)   
3,097 (15) 
HR = 0.8                
(95% CI 0.47-1.36)  
 
Non-Diabetic ‡         
(Cases of Rectal CA)    
49,652 (145) 
Diabetic ‡             
(Cases of Rectal CA)   
1,571 (8) 
HR = 1.65               
(95% CI 0.8-3.39)  
Limburg et al. 
Non-Diabetic †         
(EI of CRC)            
Not Specified (20.4)* 
Diabetic †             
(OI of CRC)           
997 (34) 
SIR = 1.67**             
(95% CI 1.16-2.33)  
 
Non-Diabetic ‡         
(EI of CRC)            
Not Specified (16.4)* 
Diabetic ‡             
(OI of CRC)           
978 (17) 
SIR = 1.03**             
(95% CI 0.6-1.66)  
Kuriki et al. 
Without CRC†         
(Case of DM)          
13,254 (945) 
With CRC†          
(Case of DM)          
686 (76) 
OR = 1.3                
(95% CI 1.0-1.68) 
Age, Body Mass Index, Alcohol, Smoking, 
Physical exercise, Bowel movement, Family 
Hx of CRC, Family Hx of DM, Vegetable 
intake, Dietary restriction 
 
Without CRC‡         
(Case of DM)          
32,789 (780) 
With CRC‡           
(Case of DM)          
527 (22) 
OR = 1.13               
(95% CI 0.72-1.76)  
Ren et al. 
Non-Diabetic †         
(EI of CRC)            
Not Specified (20.3)* 
Diabetic †             
(OI of CRC)           
3,792 (37) 
SIR = 1.82**             
(95% CI 1.23-2.4)  
 
Non-Diabetic ‡         
(EI of CRC)            
Not Specified (19.8)* 
Diabetic ‡             
(OI of CRC)           
4146 (27) 
SIR = 1.36**             
(95% CI 0.85-1.88)  
RR = Risk Ratio, HR = Hazard Ratio, SIR = Standardized Incidence Ratio, OR = Odds Ratio 
DM = Diabetes Mellitus, CRC = Colorectal Cancer, Hx = History, EI = Expected Incidence, OI = 
Observed Incidence        
† Men   ‡ Women 
* Number of EI calculated according to age & gender-specific incidence rate of general population 
** Calculated as ratio of Observed Incidence cases to Expected Incidence cases 
Table 1. Type II DM and Colorectal CA 
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These studies, taken as a whole, suggest Type II DM is associated with a moderately 
increased risk of CRC overall, with more recent studies consistently demonstrating stronger 
associations for men than for women.   
4. Implication of Type II DM on pancreatic cancer 
4.1 Etiology and pathophysiology 
The precise etiology of pancreatic cancer remains unclear.  Several environmental factors 
have been implicated, but evidence of a causative role exists only for tobacco use.   
Many epidemiologic studies have reported a positive association between DM and 
pancreatic cancer risk, with concern that diabetes may be a consequence, rather than a cause 
(Noy & Bilezikian, 1994).  However, other studies have demonstrated an association 
between elevated plasma glucose, insulin and C-peptide levels - characteristics of long-
standing DM – with increased risk for pancreatic cancer (Batty et al., 2004; Gapstur et al., 
2000; Jee, et al., 2005; Michaud, et al., 2007; Stattin, et al., 2007). 
Some studies have demonstrated an increased incidence of pancreatic cancer among 
patients with chronic pancreatitis or history of DM (Batty et al., 2009; Genkinger et al., 2009; 
Hildalgo, 2010; Landi, 2009; Lowenfels & Maisonneuve, 2006).  Though less conclusive, 
there is also evidence that chronic cirrhosis, high-cholesterol diet and previous 
cholecystectomy are associated with an increased incidence of pancreatic cancer (Batty et al., 
2009; Genkinger et al., 2009; Hildalgo, 2010; Landi, 2009; Lowenfels & Maisonneuve, 2006).  
Considerable number of recent epidemiologic studies suggests that DM may be a 
predisposing factor in pancreatic carcinogenesis (Gapstur et al., 2000).    
4.2 Epidemiologic studies 
A meta-analysis conducted by Everhart et al. has shown that a history of diabetes for greater 
than or equal to 5 years increases the incidence of pancreatic cancer by twofold (Everhart & 
Wright, 1995).  Among 20 studies included in meta-analysis, 18 demonstrated a positive 
association between preexisting diabetes and the occurrence of pancreatic cancer. The 
pooled Relative Risk (RR) of 20 epidemiologic studies for those diabetes was diagnosed at 
least 1 year prior to either diagnosis of pancreatic cancer or mortality was 2.1 with 95% CI of 
1.6-2.8.  In an analysis requiring a 5-year duration of diabetes resulted in similar results, 
with RR of 2.0 (95% CI 1.2-3.2) in 11 epidemiologic studies [Table 2].  
In a hospital based case-control study, Bonelli et al. have demonstrated that the risk of 
pancreatic cancer was increased by 6.2 fold in patients with diabetes, which necessitated 
insulin therapy for greater than 5 years (Bonelli et al., 2003). Jamal and colleagues further 
supported these findings with their large population-based case-control study of 1,172,496 
patients, by demonstrating that occurrence of pancreatic cancer was increased by 
threefold in DM patients compared to controls (frequency of pancreatic cancer in DM 
subjects 0.9% compared to control subjects 0.3% with OR:3.22, 95% CI: 3.03-3.42) (Jamal et 
al., 2009) [Table 2].    
A more recent three large case-control studies conducted by Li and colleagues have 
shown that diabetes is associated with 1.8 fold risk of pancreatic cancer (95% CI: 1.5-2.1), 
adjusted for age, sex, race, education, smoking, alcohol consumption and Body Mass 
Index (BMI).  Risk estimates decreased with increasing years with diabetes. Among 
diabetics, risk was higher in insulin users vs. non-users (OR: 2.2, 95%CI 1.6-3.7).  Insulin 
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use of >10 years was associated with reduced risk of pancreatic cancer (OR: 0.5 95% CI: 
0.3-0.9).  Lastly, Hispanic/Latino-American men and Asian-Americans had higher risks of 
diabetes-associated pancreatic cancer when compared to Caucasian-Americans and 
African-Americans, but the differences were not statistically significant (Li et al., 2011) 
[Table 2].  
 
Study Control Case 
Adjusted Risk for 
Pancreatic Cancer 
Adjustment 
Jamal et al. 
Non-Diabetic  (% 
with pancreatic 
CA)          836,283 
(0.3) 
Diabetic            (% 
with pancreatic 
CA)           278,761 
(0.9) 
OR = 3.22            
(95% CI 3.03-3.42) 
Smoking, Obesity, 
Pancreatitis and other 
Pancreatic disorders 
Li et al.† 
Without 
Pancreatic CA  (% 
with DM)         
5113 (11) 
With  
 Pancreatic CA     
(% with DM)       
2192 (20.4) 
OR = 1.8             
(95% CI 1.5-2.1) 
Age, Sex, Race, 
Education, Smoking, 
Alcohol, Body Mass 
Index, Study site 
Gapstur et al.‡ 
Non-Diabetic  
(No. of pancreatic 
CA mortality)     
16,158 (30) 
Diabetic           
(No. of pancreatic 
CA mortality)      
2,578 (23) 
RR = 2.15            
(95% CI 1.22-3.8) 
Age, Race, Categories of 
postload plasma glucose 
[ ], Smoking, Body Mass 
Index 
Everhart et al.¶ NA NA 
DM (1yr)* RR= 2.1     
(95% CI 1.6-2.8)       
DM (5yr)** RR= 2.0 
(95% CI 1.2-3.2) 
Age (Each 
epidemiologic study 
included in Meta-
analysis with own 
variables) 
Calle et al. 
Non-Diabetic  
(No. of pancreatic 
CA mortality)     
1,035,758  
(2953) 
Diabetic           
(No. of pancreatic 
CA Mortality)      
53,828 (249) 
RR = 1.48            
(95% CI 1.3-1.68) 
Age, Race, Smoking, 
Family Hx of pancreatic 
CA, Body Mass Index, 
Education 
OR = Odds Ratio, RR = Risk Ratio, CI = Confidence Interval, CA = Cancer, NA = Non- applicable,  
Hx = History, DM = Diabetes Mellitus, [ ] = Concentration, No. = Number, yr = year 
†  Data pooled from 3 case-control studies (M.D. Anderson Cancer Center Study,      
   University of California San Francisco Bay Area Study, National Cancer Institute Study) 
‡ Non-diabetic designated to participants with postload plasma glucose [ ] ≤ 119mg/dL  
   (6.6mmol/L). Diabetic designated to participants with postload plasma glucose [ ]  
   ≥ 200mg/dL (11.1mmol/L) 
  Meta-analysis: Pooled RR of 20 epidemiologic studies*  11 epidemiologic studies ** 
Table 2. Type II DM and Pancreatic CA 
Gapstur and colleagues have also demonstrated a positive association between post-load 
plasma glucose level and risk of pancreatic cancer mortality.  Risk was 2.2 fold higher (RR 
www.intechopen.com
 
Implications of Type II Diabetes Mellitus on Gastrointestinal Cancers 
 
329 
2.15 CI 1.22-3.8, p 0.01) for participants whose post load plasma glucose level was at least 
200mg/dL at baseline compared to those with less or equal to 119mg/dL, adjusted for age, 
race, cigarette smoking status and BMI.  This association was independent of other known 
and suspected pancreatic cancer risk factors such as age, race, cigaretts smoking and BMI 
(Gapstur et al., 2000) [Table 2].  
Lastly, Calle et al. have also concluded from their study, after 12 years of follow-up in 
1,089,586 men and women, that a history of self-reported diabetes was associated with 
increased pancreatic cancer mortality RR = 1.48 (95% CI 1.3-1.68) [Table 2]. This association 
was similar in men RR = 1.49 (95% CI 1.25-1.77) and women RR = 1.51 (95% CI 1.24-1.85).  
(Calle et al., 1998) [Table 2].    
These studies, taken as a whole, suggest Type II DM is independently associated with about 
two-fold increased risk in pancreatic cancer.  This finding is consistent throughout all 
studies which adjusted for tobacco use, which remains to be the only environmental factor 
that plays a causative role in the risk of pancreatic cancer.  
5. Implication of Type II DM on biliary tract cancer (primary carcinoma of 
gallbladder and extrahepatic/intrahepatic cholangiocarcinoma) 
5.1 Etiology and pathophysiology 
Type II DM is associated with insulin resistance, compensatory hyperinsulinemia and up-
regulated level of insulin-like growth factors (IGFs).  Cai and colleagues have recently 
demonstrated that IGFs may stimulate cholangiocyte growth through cellular proliferation 
and inhibition of apoptosis (Cai et al., 2008).  Furthermore, the integral role IGFs may play in 
the carcinogenesis of cholangiocytes is supported by in vitro and in vivo studies (Alvaro et 
al., 2006).   
The etiology of primary gall bladder carcinoma is not well understood.  However, several 
factors have been postulated to place patients at a greater risk.  These risk factors include 
gallstone disease, obesity, female sex, tobacco use and an anomalous pancreaticobiliary 
ductal union (Jones, 1990; Strom et al., 1995).  Some international population-based studies 
have also shown that diabetes is independently associated with a higher risk of gallstones, 
which is one of the major risk factors for primary carcinoma of the gallbladder (Festi et al., 
2008; Shebl et al., 2010).   
In a recent study by Biddinger and colleagues, the mechanistic link between the well-
documented association between gallstones and the metabolic syndrome has been proposed 
(Biddinger et al., 2008).  Their study using the LIRKO mouse model (mice with isolated 
hepatic insulin resistance created by liver-specific disruption of the insulin receptor), 
showed that hepatic insulin resistance leads to increased biliary cholesterol secretion and 
cholesterol gallstone formation, both of which are features of the human metabolic 
syndrome (Attili et al., 1997; Bennion & Grundy, 1975; Shaffer & Small, 1977).  These effects 
are due to disinhibition of the forkhead transcrtiption factor (FoxO1), which drives the 
expression of the biliary cholesterol transporters (Abcg5 and Abcg8), in addition to the 
enzymes of gluconeogenesis (Biddinger et al., 2008).   
5.2 Epidemiologic studies 
In a large population-based case-control study conducted among 1,172,496 American 
Veterans, Jamal and colleagues have found that Type II DM was associated with an increased 
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risk of gallbladder cancer.  The risk of gallbladder (OR 2.2, 95%CI 1.56-3) cancer was increased 
by two-fold in diabetic patients when compared to controls (Jamal et al., 2009) [Table 3]. A 
case-control study using a large United Kingdom primary care database,  Grainge et al. also 
demonstrated that the relative risk of gallbladder cancer in diabetic patients compared to non-
diabetic controls was 1.43 (95% CI: 0.81-2.52) (Grainge et al., 2009) [Table 3].    
A similar analysis was performed by investigators, Shebl and colleagues in a population-
based case-control study of 627 biliary tract cancers, 1037 biliary tract stones, and 959 
controls in Shanghai, China.  Independent of BMI, diabetes was associated with significantly 
increased risks of gallbladder cancer and biliary stones, OR 2.6 (95% CI 1.5-4.7) and 2.0 (95% 
CI 1.2-3.3), respectively. Furthermore, about 60% of the effect of diabetes on biliary tract 
cancer was mediated in part by gallstones and 17% by high-density lipoprotein (HDL). 
However, no significant association was found with extrahepatic biliary cancer and cancer 
of Ampulla of Vater. (Shebl et al., 2010) [Table 3]. 
 
Study Control Case 
Adjusted OR for 
Biliary Tract 
Cancer 
Adjustment 
Jamal et al.†‡ 
Non-Diabetic 
(% with Gallbladder 
 CA)  
 836,283 (0) 
Diabetic 
(% with Gallbladder  
CA) 
 278,761 (0.03) 
OR = 2.2  
(95% CI 1.56-3.0) 
Gallstone disease, 
Smoking, Obesity 
 
Non-Diabetic  
(% with Extrahepatic  
Biliary CA)  
836,283 (0.02) 
Diabetic 
(% with Extrahepatic  
Biliary CA) 
278,761 (0.1) 
OR = 2.1              
(95% CI 1.61-2.53)  
Grainge et al.†‡ 
Without 
Gallbladder CA  
(% DM)  
5760 (5.9) 
With 
Gallbladder CA 
(% DM)  
5760 (8.7) 
OR = 1.43             
(95% CI 0.81-2.52) 
Sex, Age 
 
Without  
Cholangiocarcinoma (% DM) 
5760 (5.9) 
With  
Cholangiocarcinoma (% DM) 
 372 (9.4) 
OR = 1.48             
(95% CI 1.0-2.17)  
Shebl et al.† 
Without  
 Gallbladder CA  
(% DM)  
 902 (7.54) 
With 
Gallbladder CA  
(% DM)  
367 (13.9) 
OR = 2.63             
(95% CI 1.47-4.68) 
Age, Sex, Education, 
Diabetes duration, 
Body Mass Index, 
Waist-to-hip ratio, 
Aspirin use 
Welzel et al.‡ 
Without  
ECC  (% DM) 
102,782 (22.1) 
With 
ECC  (% DM)  
549 (30.1) 
OR = 1.5              
(95% CI 1.3-1.8) 
Age, Sex, Race, 
Geographic location 
 
Without 
ICC (% DM) 
102,782 (22.1) 
With 
ICC (% DM) 
535 (33.1) 
OR = 1.8              
(95% CI 1.5-2.1)  
Tao et al.‡ 
Without  
ECC (% DM) 
 380 (9.5) 
With 
ECC (% DM)  
129 (18.6) 
OR = 3.2              
(95% CI 1.7-5.9) 
Age, Sex, DM, 
Cholelithiasis, Hx of 
Cholecystectomy 
 
Without  
 ICC (% DM)  
380 (9.5) 
With 
ICC  (% DM) 
6.1 (4.9) 
NA 
 
OR = Odds Ratio, CI = Confidence Interval, CA = Cancer, NA = Non-applicable 
Hx = History, DM = Diabetes Mellitus, ECC = Extrahepatic Cholangiocarcinoma 
ICC = Intrahepatic Cholangiocarcinoma 
† Gallbladder CA 
‡ Extrahepatic and/or Intrahepatic Cholangiocarcinoma  
Table 3. Type II DM and Biliary Tract CA 
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However, several other studies have shown that there is significant association between 
Type II DM and bile duct cancers.  Jamal et al. in the same large population-based case-
control study, described above, showed that extrahepatic biliary cancer was increased by 
two-fold in diabetic patients (OR 2.1, 95% 1.61-2.53) (Jamal et al., 2009). Grainge and 
colleagues, in their large UK study, described above, also support the finding of increased 
risk of cholangiocarcinoma in diabetic patients compared to non-diabetic controls (RR = 
1.48, 95% CI: 1.0-2.17) (Grainge et al., 2009) [Table 3].    
Welzel et al. further demonstrated that Type II DM was significantly more common among 
both Extrahepatic Cholangiocarcinoma (ECC) and Intrahepatic Cholangiocarcinoma (ICC).  
The study examined the prevalence of following risk factors for both ECC and ICC in 
patients age 65 years and older with diagnosis of ECC or ICC using the SEER (Surveillance, 
Epidemiology, and End Results) database in the United States: Biliary cirrhosis, 
cholelithiasis, choledocholithiasis, cholecystitis, cholecystectomy, alcoholic liver disease, 
liver cirrhosis, Type II DM, thyrotoxicosis and chronic pancreatitis.  Prevalence of Type II 
DM was significantly higher in patients with ECC compared to those without ECC (OR = 
1.5, 95% CI 1.3-1.8).  Similar result was found in patients with ICC compared to those 
without ICC (OR = 1.8, 95% CI 1.5-2.1) [Table 3].  
A similar study was conducted by investigators in China by Tao and colleagues, who also 
supported Welzel’s findings that Type II DM had a positive association with ECC (OR = 3.2, 
95% CI 1.7-5.9), adjusted for age, gender, history of cholelithiasis and cholecystectomy.  
However, in this Chinese population-based study, an inverse association between Type II 
DM and ICC were reported (increased DM cases among patients with ICC than those 
without ICC) (Tao et al., 2009) [Table 3]. 
6. Implication of Type II DM on hepatocellular carcinoma 
6.1 Etiology and pathophysiology 
The main etiology of hepatocellular carcinoma (HCC) is chronic infection with hepatitis B 
and hepatitis C viruses.  However, there are other important factors that contribute to the 
international burden of HCC.  Among these are obesity, diabetes, non-alcoholic 
steatohepatitis (NASH) and dietary exposures (Blonski et al, 2010).  Diabetes is a part of the 
metabolic syndrome that is characterized by insulin resistance and is thought to predispose 
to nonalcoholic fatty liver disease (NAFLD), including its more severe form, nonalcoholic 
steatohepatitis (NASH) (El-Serag, et al., 2006).  Diabetes has also been identified as an 
independent factor for disease progression and for more advanced liver disease in patients 
with NAFLD.   
HCC as a complication of diabetes-associated NASH has been described (Di Bisceglie et al., 
1998; El-Serag et al., 2001) and diabetes has been found to be prevalent in patients with HCC 
and cryptogenic cirrhosis (Marchesini et al., 1999; Matteoni et al., 1999).  However, the 
pathophysiology underlying the increased risk of chronic nonalcoholic liver disease and 
HCC with diabetes is uncertain.  Proposed pathyphysiology involves increased insulin 
resistance in NAFLD patients compared with control subjects (Marchesini et al., 1999).  
Insulin resistance facilitates peripheral lipolysis, decreases mitochondrial beta-oxidation of 
fatty acids and increases accumulation of free fatty acids in the liver, which can lead to 
NAFLD (Chitturi & Farrell, 2001; Pessayre et al., 2001).  Recent studies have shown that 
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HCC can result as a consequence of DM-related NASH (Cotrim et al., 2000; Shimada et al., 
2002; Zen et al., 2001).  
6.2 Epidemiologic studies 
In a large retrospective cohort study of veteran patient populations (DM cohort: 173,643. 
Control: 650,620), El-Serag and colleagues have shown that the incidence of chronic 
nonalcoholic fatty liver disease (NAFLD) was significantly higher among patients with 
diabetes compared to control patients (Incidence rate: 18.13 vs. 9.55 per 10,000 person-years, 
respectively).  Corresponding results were obtained for higher rates of HCC among diabetic 
patients compared to non-diabetic patients (incidence rate: 2.39 vs. 0.87 per 10,000 person-
years, respectively), supporting previously published studies with positive association 
between Type II DM and HCC (El-Serag et al., 2004).    
Furthermore, in a recent systematic review of 13 case-control studies, 11 supported an 
association between diabetes and the development of HCC.  Among the 13 case-control 
studies, subjects with diabetes were found to have a two-fold increase in the risk of HCC.  This 
association was also appreciated amongst 12 cohort studies evaluated (El-Serag et al., 2006). 
7. Conclusion 
Type II Diabetes Mellitus and its complications is a growing public health problem 
worldwide.  Increased morbidity and mortality associated with various gastrointestinal 
cancers as one of the complications of Type II DM holds strong public health and clinical 
relevance.  There is a growing body of evidence suggesting that Type II DM and its 
metabolic defects (hyperinsulinemia and hyperglycemia) are associated with increased risk 
of various gastrointestinal cancers.  Although further studies are required to definitively 
validate this association, the current understanding between Type II DM and 
gastrointestinal cancers warrants attention for its potential implications in the clinical 
practice of diabetic management and novel targeted cancer therapy.    
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